Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
Adrian Towse and
Consulting Reports from Office of Health Economics
The report addresses the implications of NICE appraising treatments for very rare diseases using a cost-per-QALY gained decision rule of the type used by NICE in its Technology Appraisal Programme to appraise therapies for more common conditions. Given the importance of non-QALY elements in the assessment of HSTs, such as treatment impact on the process of care and on the patients' or their carers' ability to go to school or to work respectively, and issues in measuring quality of life when the population affected are infants or young children, it is inappropriate to focus the appraisal of treatments for very rare diseases solely on a cost-per-QALY measure. Given the lack of empirical basis, the new £100,000 cost per QALY threshold and its further possible uplift up by a factor of three seem arbitrary.
Keywords: Judging; value; for; money; and; improving; decision; making (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
New Economics Papers: this item is included in nep-hea
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
https://www.ohe.org/system/files/private/publicati ... a-orphan%20drugs.pdf (application/pdf)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:ohe:conrep:001978
Access Statistics for this paper
More papers in Consulting Reports from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ().